Back to results
US 2026/0168998 A1Published application
Diagnosis of congenital cytomegalovirus infection
AssigneeHadasit Medical Research Services and Development Ltd.
InventorDana Wolf
Life of this patent
Estimating the term…
Abstract
The present invention provides biomarkers allowing the diagnosis of symptomatic congenital cytomegalovirus (CMV) infection and in particular to differentiate between symptomatic and asymptomatic infected fetuses, methods of diagnosis of CMV using said biomarkers, diagnostic kits comprising thereof, and use of the kits and methods of diagnosing fetuses infected with a symptomatic congenital cytomegalovirus (CMV).
Claims20
A method for recommending a medical intervention, the method comprising:
- detecting whether a fetus has a symptomatic congenital cytomegalovirus (cCMV) and providing recommendation of a medical intervention, wherein detecting a symptomatic congenital cytomegalovirus comprises:
- (i) determining a level of at least one biomarker in a biological sample;
- and
- (ii) comparing the level of the at least one biomarker from the biological sample to its level in a control, wherein a difference in the level of the biomarker in the biological sample and in the control is indicative of presence of the symptomatic cCMV infection, wherein the at least one biomarker is selected from RARRES2, LGALS3BP, GPNMB, Nesprin-1 (SYNE1), Myosin-14 (MYH14), Carboxypeptidase A2 (CPA2), Secretoglobin family 3A member 2 (SCGB3A2)C-reactive protein (CRP), Glutathione S-transferase theta-1 (GSTT1), Carboxypeptidase Q Protein (CPQ);
- Family with sequence similarity 3 member D (FAM3D);
- Keratin 17 (KRT17);
- Angiopoietin-related protein 6 (ANGPTL6), CPM, Platelet-derived growth factor receptor beta (PDGFRB), Dermokine (DMKN), Secretogranin-1 (CHGB), ADAM9, Growth arrest-specific protein 1 (GAS1), Platelet basic protein (PPBP), Platelet glycoprotein Ib alpha chain (GP1BA), Lysosome-associated membrane glycoprotein 2 (LAMP2), Neurofascin (NFASC), Alcohol dehydrogenase [NADP(+)] (AKR1A1), Heat shock protein beta-1 (HSPB1), Maltase-glucoamylase (MGAM), Actin alpha 1, skeletal muscle (ACTA1), Mesothelin (MSLN);
- Sarcoglycan epsilon (SGCE);
- Cell growth regulator with EF hand domain protein 1 (CGREF1);
- and Endoplasmic reticulum aminopeptidase 1 (ERAP1),
- wherein the biomarkers RARRES2, LGALS3BP, GPNMB, SYNE1, MYH14, CPA2, SCGB3A2, CRP, GSTT1, CPQ, FAM3D, and KRT17 are collectively referred to as biomarkers of Group C and biomarkers ANGPTL6, CPM, PDGFRB, DMKN, CHGB, ADAM9, GAS1, PPBP, GP1BA, LAMP2, NFASC, AKR1A1, HSPB1, MGAM, AACTA1, MSLN, SGCE, CGREF1, and ERAP1 are collectively referred to as biomarkers of Group D.
8 more elements
A method of treating a congenital cytomegalovirus infection in a fetus, the method comprising:
- diagnosing the symptomatic cCMV in fetus and administering to the fetus or the mother an anti-CMV active agent, wherein diagnosing the symptomatic cCMV in fetus comprises:
- (i) determining a level of at least one biomarker in a biological sample;
- and
- (ii) comparing the level of the at least one biomarker from the biological sample to its level in a control, wherein a difference in the level of the biomarker in the biological sample and in the control is indicative of the presence of symptomatic cCMV infection, wherein the at least one biomarker is selected from RARRES2, LGALS3BP, GPNMB, Nesprin-1 (SYNE1), Myosin-14 (MYH14), Carboxypeptidase A2 (CPA2), Secretoglobin family 3A member 2 (SCGB3A2)C-reactive protein (CRP), and Glutathione S-transferase theta-1 (GSTT1);
- Carboxypeptidase Q Protein (CPQ);
- Family with sequence similarity 3 member D (FAM3D);
- Keratin 17 (KRT17), CPM, Platelet-derived growth factor receptor beta (PDGFRB), Angiopoietin-related protein 6 (ANGPTL6), Dermokine (DMKN), Secretogranin-1 (CHGB), ADAM9, Growth arrest-specific protein 1 (GAS1), Platelet basic protein (PPBP), Platelet glycoprotein Ib alpha chain (GP1BA), Lysosome-associated membrane glycoprotein 2 (LAMP2), Neurofascin (NFASC), Alcohol dehydrogenase [NADP (+)] (AKR1A1), Heat shock protein beta-1 (HSPB1), Maltase-glucoamylase (MGAM), LAMP2 and Actin alpha 1, skeletal muscle (ACTA1), Mesothelin (MSLN);
- Sarcoglycan epsilon (SGCE);
- Cell growth regulator with EF hand domain protein 1 (CGREF1);
- and Endoplasmic reticulum aminopeptidase 1 (ERAP1);
- wherein the biomarkers RARRES2, LGALS3BP, GPNMB, SYNE1, MYH14, CPA2, SCGB3A2, CRP, GSTT1, CPQ, FAM3D, and KRT17 are collectively referred to as biomarkers of Group C, and biomarkers ANGPTL6, CPM, PDGFRB, DMKN, CHGB, ADAM9, GAS1, PPBP, GP1BA, LAMP2, NFASC, AKR1A1, HSPB1, MGAM, AACTA1, MSLN, SGCE, CGREF1, and ERAP1 are collectively referred to as biomarkers of Group D.
8 more elements
A kit, comprising:
- means for determining levels of at least two biomarkers in a biological sample;
- wherein the at least two biomarkers are selected from the group consisting of biomarkers of Group C and Group D, and instructions for use.
Dependencies are inferred from the claim text.